Spending less time in slow wave and REM sleep may accelerate brain atrophy in regions affected early in Alzheimer’s disease, ...

More morning naps were associated with a higher risk of Alzheimer's dementia, while more early afternoon naps were tied to reduced amyloid levels, data from the Rush Memory and Aging Project showed.

Using physically active transportation modes in midlife -- particularly cycling -- was tied to lower dementia risk and ...

NewAmsterdam Pharma (NASDAQ: NAMS) has announced positive topline data from the prespecified Alzheimer’s disease ("AD") ...

NewAmsterdam Pharma’s push to show a cholesterol drug can prevent Alzheimer’s disease has passed another test. | NewAmsterdam ...

Pre-specified analyses show that obicetrapib treatment leads to statistically significant and clinically meaningful reductions in the primary outcome measure of Alzheimer's disease biomarker in both ...

Pre-specified analyses show that obicetrapib treatment leads to statistically significant and clinically meaningful reductions in the primary outc ...

Patients with Alzheimer disease and cognitive impairment with delayed REM sleep patterns have increased levels of brain amyloid and tau.

ApoE4 carriers have a substantially higher risk of developing ARIA, so Alzheimer’s patients who carry this genetic variant could benefit from a drug offering a different approach. While Leqembi ...

Topline results were announced from a phase 3 trial evaluating valiltramiprosate (ALZ-801) in apolipoprotein ε4 allele (APOE4) carriers with early Alzheimer disease (AD). Valiltramiprosate is an ...

For Parkinson’s, we will take a deeper look into the cognitive response, while for Alzheimer’s, we will dive into the advantages of buntanetap for APOE4 carriers, addressing a pressing challenge in ...

1Hey JA, et al: Clinical Pharmacokinetics of Oral ALZ-801/Valiltramiprosate in a Two-Year Phase 2 Trial of APOE4 Carriers with Early Alzheimer’s Disease, Clinical Pharmacokinetics 2025.